# 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is K101574.

807.92 (a)(1): Name:

ARK Diagnostics, Inc.

Address:

1190 Bordeaux Drive Sunnyvale, CA 94089

Owner Operator Number: 10027663   
Establishment Registration: 3005755244

Phone: (408) 747-0700   
FAX: (408) 747-0783   
Contact: Kenneth C. Kasper, PhD - (408) 747-0708 Executive Director of Quality and Regulatory Affairs

Date prepared: November 23, 2010

807.92 (a)(2): Device name- trade name and common name, and classification

Trade name:

ARKTM Gabapentin Assay ARK™M Gabapentin Calibrator ARKTM Gabapentin Control

Common Name: Homogeneous Enzyme Immunoassay

Classification: 21 CFR 862.3350 NWM Diphenylhydantoin Test System; Class II (21 CFR 862.3200 DLJ, 21 CFR 862.3280 LAS)

# 807.92 (a)(3): Identification of the legally marketed predicate device

ARK™M Topiramate Assay ARKTM Topiramate Calibrator ARKTM Topiramate Control

K083799 (bundled)

# 807.92 (a)(4): Device Description

The ARK Gabapentin Assay is a homogeneous immunoassay based on competition between drug in the specimen and gabapentin labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for binding to the antibody reagent. As the latter binds antibody, enzyme activity decreases. In the presence of drug from the specimen, enzyme activity increases and is directly proportional to the drug concentration. Active enzyme converts the coenzyme nicotinamide adenine dinucleotide (NAD) to NADH that is measured spectrophotometrically as a rate of change in absorbance. Endogenous serum G6PDH does not interfere with the results because the coenyzme NAD functions only with the bacterial enzyme used in the assay.

The ARK Gabapentin Assay consists of reagents R1 anti-gabapentin polyclonal antibody with substrate and R2 gabapentin labeled with bacterial G6PDH enzyme. The ARK Gabapentin Calibrator consists of a six-level set to calibrate the assay, and the ARK Gabapentin Control consists o a three-level set used or quality control of theassy.

ARK Gabapentin products contain $\leq 0 . 0 9 \%$ sodium azide. As a precaution, affected plumbing should be flushed adequately with water to mitigate the potential accumulation of explosive metal azides. No special handling is requiredregardingotherassay components.

# 807.92 (a)(5): Intended Use / Indications for Use

The ARK™M Gabapentin Assay is a homogeneous enzyme immunoassay intended for the quantitative determination of gabapentin in human serum or plasma on automated clinical chemistry analyzers. Gabapentin concentrations can be used as an aid in management of patients treated with gabapentin.

The ARKTM Gabapentin Calibrator is intended for use in calibration of the ARK Gabapentin Assay.

The ARKTM Gabapentin Control is intended for use in quality control of the ARK Gabapentin Assay.

# 807.92 (a)(6): Technological Similarities and Differences to the Predicate

# SUBSTANTIAL EQUIVALENCE COMPARATIVE CHART

Comparison between the ARK Gabapentin Assay and the RK Topiramate Assay   

<table><tr><td rowspan=1 colspan=1>Characteristic</td><td rowspan=1 colspan=1>DeviceARK™M Gabapentin Assay</td><td rowspan=1 colspan=1>PredicateARKTM Topiramate Assay K083799</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The ARKTM Gabapentin Assay is intendedfor the quantitative determination ofgabapentin in human serum or plasma onautomated clinical chemistry analyzers.</td><td rowspan=1 colspan=1>The ARK TM Topiramate Assay is intendedfor the quantitative determination oftopiramate in human serum or plasma onautomated clinical chemistry analyzers.</td></tr><tr><td rowspan=1 colspan=1>Indications for Use</td><td rowspan=1 colspan=1>Gabapentin concentrations can be used as anaid in management of patients treated withgabapentin.</td><td rowspan=1 colspan=1>The results obtained are used in the diagnosisand treatment of topiramate overdose and inmonitoring levels of topiramate to helpensure appropriate therapy.</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Serum or plasma</td><td rowspan=1 colspan=1>Serum or plasma</td></tr><tr><td rowspan=1 colspan=1>Methodology</td><td rowspan=1 colspan=1>Homogenous enzyme immunoassay (EIA)</td><td rowspan=1 colspan=1>Homogenous enzyme immunoassay (EIA)</td></tr><tr><td rowspan=1 colspan=1>ReagentComponents</td><td rowspan=1 colspan=1>Two (2) reagent system:Anti- gabapentin Antibody/SubstrateReagent (R1) containing rabbit polyclonalantibodies to gabapentin, glucose-6-phosphate, nicotinamide adeninedinucleotide, bovine serum albumin, sodiumazide, and stabilizersEnzyme Reagent (R2) containing gabapentinlabeled with bacterial G6PDH, buffer, bovineserum albumin, sodium azide, and stabilizers</td><td rowspan=1 colspan=1>Two (2) reagent system:Anti-topiramate Antibody/Substrate Reagent(R1) containing rabbit polyclonal antibodiesto an epitope of topiramate, glucose-6-phosphate, nicotinamide adeninedinucleotide, bovine serum albumin,preservatives, and stabilizersEnzyme Reagent (R2) containing topiramateepitope labeled with bacterial G6PDH,buffer, bovine serum albumin, preservatives,and stabilizers</td></tr><tr><td rowspan=1 colspan=1>Platform required</td><td rowspan=1 colspan=1>Automated clinical chemistry analyzer</td><td rowspan=1 colspan=1>Automated clinical chemistry analyzer</td></tr><tr><td rowspan=1 colspan=1>Accessory reagents</td><td rowspan=1 colspan=1>Calibrators (six levels) and controls (threelevels)</td><td rowspan=1 colspan=1>Calibrators (six levels) and controls (threelevels)</td></tr><tr><td rowspan=1 colspan=1>Testingenvironment</td><td rowspan=1 colspan=1>Routine clinical laboratory</td><td rowspan=1 colspan=1>Routine clinical laboratory</td></tr><tr><td rowspan=1 colspan=1>Reagent conditionand storage</td><td rowspan=1 colspan=1>Liquid, 2-8° C</td><td rowspan=1 colspan=1>Liquid, 2-8° C</td></tr></table>

# 807.92 (b)(1) and 807.92 (b)(2): Brief Description of Nonclinical and Clinical Data

# Limit of Quantitation (LOQ)

The LOQ of the ARK Gabapentin Assay was determined according to CLSI EP17-A and is defined as the lowest concentration for which acceptable inter-assay precision and recovery observed $( \leq 2 0 \%$ CV with $\pm 1 5 \%$ recovery). The LOQ was determined to be $0 . 7 5 \mu \mathrm { g / m L }$ .

# Recovery

Accuracy (analytical recovery) was performed by adding concentrated gabapentin drug into human serum negative for gabapentin. A stock concentrate of highly pure gabapentin was added volumetrically to human serum negative for gabapentin, representing drug concentrations across the assay range. Six replicates of each sample were assayed on an automated clinical chemistry analyzer. The results were averaged and compared to the target concentration and percent recovery calculated. Results are shown below.

$\%$ Recovery $= 1 0 0$ X Mean recovered concentration Theoretical concentration

<table><tr><td>Theoretical Concentration (μg/mL)</td><td>Mean Recovered Concentration (μg/mL)</td><td>Percent Recovery</td></tr><tr><td>1.0</td><td>0.99</td><td>98.5</td></tr><tr><td>2.0</td><td>2.07</td><td>103.3</td></tr><tr><td>3.5</td><td>3.55</td><td>101.3</td></tr><tr><td>9.0</td><td>8.98</td><td>99.7</td></tr><tr><td>16.0</td><td>16.03</td><td>100.2</td></tr><tr><td>22.0</td><td>22.00</td><td>100.0</td></tr><tr><td>28.0</td><td>27.85</td><td>99.5</td></tr><tr><td>35.0</td><td>35.59</td><td>101.7</td></tr><tr><td>40.0</td><td>41.49</td><td>103.7</td></tr></table>

Mean percent recovery: $1 0 0 . 9 \%$

# Linearity

Linearity studies were performed as suggested in CLSI/NCCLS Protocol EP6-A. A $4 8 . 0 ~ \mu \mathrm { g / m L }$ EY serum sample was prepared and dilutions were made proportionally with human serum negative for gabapentin. Gabapentin concentrations ranged from 0.75 to $4 8 . 0 ~ \mu \mathrm { g / m L }$ . Linearity at specific dilutions was considered acceptable if the percent difference was $\pm 1 0 \%$ between the predicted $1 ^ { \mathfrak { s t } }$ and 2nd order regressed values or $\pm 1 5 \% \leq 1 . 0 ~ \mu \mathrm { g / m L }$ .A linear relationship was demonstrated between 0.75 and $4 8 . 0 \mu \mathrm { g / m L }$ .Results are shown below.

<table><tr><td rowspan=1 colspan=1>Theoretical(μg/mL)</td><td rowspan=1 colspan=1>Results(μg/mL)</td><td rowspan=1 colspan=1>1st OrderPredictedResults</td><td rowspan=1 colspan=1>2nd OrderPredictedResults</td><td rowspan=1 colspan=1>% Difference</td></tr><tr><td rowspan=1 colspan=1>0.75</td><td rowspan=1 colspan=1>0.73</td><td rowspan=1 colspan=1>0.76</td><td rowspan=1 colspan=1>0.85</td><td rowspan=1 colspan=1>12.0</td></tr><tr><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>8.4</td></tr><tr><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>1.1</td></tr><tr><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>0.0</td></tr><tr><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>7.9</td><td rowspan=1 colspan=1>-0.7</td></tr><tr><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>11.9</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>11.9</td><td rowspan=1 colspan=1>-0.9</td></tr><tr><td rowspan=1 colspan=1>24.0</td><td rowspan=1 colspan=1>23.6</td><td rowspan=1 colspan=1>23.9</td><td rowspan=1 colspan=1>23.8</td><td rowspan=1 colspan=1>-0.6</td></tr><tr><td rowspan=1 colspan=1>32.0</td><td rowspan=1 colspan=1>31.8</td><td rowspan=1 colspan=1>31.9</td><td rowspan=1 colspan=1>31.8</td><td rowspan=1 colspan=1>-0.3</td></tr><tr><td rowspan=1 colspan=1>40.0</td><td rowspan=1 colspan=1>39.7</td><td rowspan=1 colspan=1>39.8</td><td rowspan=1 colspan=1>39.9</td><td rowspan=1 colspan=1>0.2</td></tr><tr><td rowspan=1 colspan=1>48.0*</td><td rowspan=1 colspan=1>48.1</td><td rowspan=1 colspan=1>47.8</td><td rowspan=1 colspan=1>48.1</td><td rowspan=1 colspan=1>0.6</td></tr></table>

\*Concentration exceeds the reportable limit.

# Assay Range

The range of the assay is 0.75 to 40.0 µg/mL. Report results below this range as <0.75 µg/mL or below the analyzer-specific lower LOQ established in your laboratory. Report results above this range as $> 4 0 . 0 ~ \mu \mathrm { g / m L }$ orbove he nalyzerspecii upperLOQ eablishe your aboaty.

Spemens testin initially above the asy range may be diluted n CalibrarA and reteted Multiply the assay result by the dilution factor to obtain the concentration of gabapentin in the undiluted specimen. A dilution factor of 4 is suggested.

# Method Comparison

Correlation studies were performed using CLSI/NCCLS Protocol EP9-A2. Results from the ARK Gabapentin Assay were compared with results from three study sites using high performance liquid chromatography  mass spectrometry methods (LC-MS/MS, Study 1), HPLC (Study 2) and LC-MS/MS (Study 3).

# Study 1

Gabapentin concentrations by LC-MS/MS ranged 1.0 to $3 9 . 0 ~ \mu \mathrm { g / m L }$ ARK gabapentin values ranged 0.6 to $3 4 . 4 ~ \mu \mathrm { g / m L }$ Reut ssgBabloes naly shown below (with $9 5 \%$ confidence limits).

Slope 0.96 (0.92 to 0.99)y-intercept -0.06 ( - 0.28 to 0.18)Correlation Coefficient $( { \bf r } ^ { 2 } )$ 0.96 (0.95 to 0.97)Number of Samples 183

![](images/f7ca3d357a45dd20ebdd42f9afc6dde74413e22156158751a7d3c82a0c6ddde8.jpg)

# Study 2

Gabapentin concentrations by HPLC ranged from 1.8 to $2 9 . 4 \ \mu \mathrm { g / m L }$ . ARK gabapentin values ranged 1. to $3 2 . 6 ~ \mu \mathrm { g } / \mathrm { m L }$   
shown below (with $9 5 \%$ confidence limits).

Slope 1.08 (1.03 to 1.13) y-intercept -0.08 ( - 0.35 to 0.25) Correlation Coefficient $( { \mathfrak { r } } ^ { 2 } )$ EY 0.97 (0.95 to 0.98) Number of Samples 64

![](images/6f3359e4349e55df39d0c8923836ada7dc1b82a7533860ddc4bbd7dbea64b004.jpg)

# Study 3

Gabapentin concentrations by LC-MS/MS ranged 1.4 to 29.6 $\mu \mathrm { g / m L }$ . ARK gabapentin values ranged 1.6 to $3 2 . 6 ~ \mu \mathrm { g } / \mathrm { m L }$ Result  sin-Babloresi analys  h shown below (with $9 5 \%$ confidence limits).

Slope 1.13 (1.08 to 1.17) y-intercept 0.31 (0.06 to 0.52) Correlation Coefficient $( { \mathfrak { r } } ^ { 2 } )$ 0.98 (0.97 to 0.99) Number of Samples 49

![](images/271070a4cfab864e56a9832119327534e80fc4d0857a5fbaabdaff170a2dcd09.jpg)

Precision was determined as described in CLSI/NCCLS Protocol EP5-A2. Tri-level controls and three human serum pooled specimens containing gabapentin were used in the study. Each level was assayed in quadruplicate twice a day for 20 days. Each of the runs per day was separated by at least two hours. The within run, between day, total SD, and percent CVs were calculated. Results are shown below. Acceptance criteria: ${ < } 1 0 \%$ total CV.

<table><tr><td></td><td></td><td></td><td colspan="2">Within Run</td><td colspan="2">Between Day</td><td colspan="2">Total</td></tr><tr><td>Sample</td><td>N</td><td>Mean (μg/mL)</td><td>SD</td><td>CV (%)</td><td>SD</td><td>CV (%)</td><td>SD</td><td>CV (%)</td></tr><tr><td colspan="9">ARK Gabapentin Control</td></tr><tr><td>LOW</td><td>160</td><td>2.5</td><td>0.08</td><td>3.3</td><td>0.10</td><td>3.9</td><td>0.14</td><td>5.6</td></tr><tr><td>MID</td><td>160</td><td>7.9</td><td>0.21</td><td>2.6</td><td>0.26</td><td>3.3</td><td>0.35</td><td>4.4</td></tr><tr><td>HIGH</td><td>160</td><td>24.6</td><td>0.48</td><td>1.9</td><td>0.65</td><td>2.7</td><td>0.88</td><td>3.6</td></tr><tr><td colspan="9">Human Serum</td></tr><tr><td>LOW</td><td>160</td><td>2.2</td><td>0.11</td><td>4.7</td><td>0.11</td><td>4.8</td><td>0.17</td><td>7.7</td></tr><tr><td>MID</td><td>160</td><td>7.3</td><td>0.58</td><td>2.4</td><td>0.25</td><td>3.4</td><td>0.33</td><td>4.6</td></tr><tr><td>HIGH</td><td>160</td><td>24.9</td><td>0.54</td><td>2.2</td><td>0.97</td><td>3.9</td><td>1.17</td><td>4.7</td></tr></table>

Interference studies were conducted using CLSI/NCCLS Protocol EP7-A2 as a guideline. Clinically high concentrations of the following potentially interfering substances in serum with known levels of gabapentin (approximately 2 and $2 0 ~ \mu \mathrm { g / m L }$ ) were evaluated. Each sample was assayed using the ARK Gabapentin Assay, along with a serum control of gabapentin. Measurement of gabapentin resulted in $\leq 1 0 \%$ error in the presence of interfering substances at the levels tested.

<table><tr><td colspan="2"></td><td colspan="2">Percentage Recovery</td></tr><tr><td>Interfering Substance</td><td>Interferent Concentration</td><td>2 μg/mL Gabapentin</td><td>20 μg/mL Gabapentin</td></tr><tr><td>Albumin</td><td>12 g/dL</td><td>102.1</td><td>98.2</td></tr><tr><td>Bilirubin Conjugated</td><td>70 mg/dL</td><td>95.2</td><td>98.3</td></tr><tr><td>Bilirubin Unconjugated</td><td>70 mg/dL</td><td>106.6</td><td>98.4</td></tr><tr><td>Cholesterol</td><td>623 mg/dL</td><td>101.6</td><td>98.0</td></tr><tr><td>Gamma-Globulin</td><td>12 g/dL</td><td>103.2</td><td>99.7</td></tr><tr><td>Hemoglobin</td><td>1000 mg/dL</td><td>102.5</td><td>101.6</td></tr><tr><td>Intralipid</td><td>1500 mg/dL</td><td>97.0</td><td>99.2</td></tr><tr><td>Rheumatoid Factor</td><td>1100 IU/mL</td><td>97.0</td><td>97.1</td></tr><tr><td>Triglycerides</td><td>1220 mg/dL</td><td>105.6</td><td>99.6</td></tr><tr><td>Uric Acid</td><td>30 mg/dL</td><td>106.6&#x27;</td><td>97.9</td></tr></table>

# Specificity

Gabapentin is eliminated from the systemic circulation solely by renal excretion as unchanged drug and is ot appreciably metabolized in humans.Therefore, no metabolites are known to result that could interfer in the measurement of gabapentin.

Medications that may be routinely co-administered with gabapentin, anti-epileptic drugs or Lamino acids were tested to determine whether these compounds affect the quantitation of gabapentin concentrations using the ARK Gabapentin Assay. High levels of these compounds were spiked into serum pools containing low (2 µg/mL) and high (20 μg/mL) therapeutic levels of gabapentin. The samples were analyzed and the gabapentin concentrations of samples containing co-administered with gabapentin, anti-epileptic drugs or L-amino acids were compared to the serum control.

Gabapentin-selective antibody did not crossreact with most other anti-epileptic or coadministered drugs tested. Due to structural similarities with gabapentin, high pregabalin levels may interfere. A high concentration of each compound was spiked into normal human serum with known levels of gabapentin (approximately 2 and $2 0 ~ \mu \mathrm { g / m L } ,$ and assayed along with a serum control of gabapentin. Measurement of gabapentin resulted in $\leq 1 0 \%$ error in the presence of drug compounds at the levels tested.

<table><tr><td rowspan=2 colspan=1>Compound</td><td rowspan=2 colspan=1>Concentration(μg/mL)</td><td rowspan=1 colspan=2>Percentage Recovery</td></tr><tr><td rowspan=1 colspan=1>Gabapentin(2 μg/mL)</td><td rowspan=1 colspan=1>Gabapentin(20 μg/mL)</td></tr><tr><td rowspan=1 colspan=1>γ-Aminobutyric Acid</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>97.8</td><td rowspan=1 colspan=1>99.2</td></tr><tr><td rowspan=1 colspan=1>L-2-Aminobutyric Acid</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>98.6</td><td rowspan=1 colspan=1>99.2</td></tr><tr><td rowspan=1 colspan=1>Acetaminophen</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>98.7</td><td rowspan=1 colspan=1>98.1</td></tr><tr><td rowspan=1 colspan=1>Acetazolamide</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>99.2</td><td rowspan=1 colspan=1>98.6</td></tr><tr><td rowspan=1 colspan=1>Acetylsalicylic acid</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>100.6</td><td rowspan=1 colspan=1>100.4</td></tr><tr><td rowspan=1 colspan=1>Amikacin</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100.2</td><td rowspan=1 colspan=1>98.7</td></tr><tr><td rowspan=1 colspan=1>Amitriptyline</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>98.2</td><td rowspan=1 colspan=1>97.9</td></tr><tr><td rowspan=1 colspan=1>Amoxapine</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>98.9</td><td rowspan=1 colspan=1>99.6</td></tr><tr><td rowspan=1 colspan=1>Amphotericin B</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>98.2</td><td rowspan=1 colspan=1>98.2</td></tr><tr><td rowspan=1 colspan=1>Ampicillin</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100.8</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>97.3</td><td rowspan=1 colspan=1>98.3</td></tr><tr><td rowspan=1 colspan=1>Baclofen</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>103.3</td><td rowspan=1 colspan=1>100.6</td></tr><tr><td rowspan=1 colspan=1>Buproprion</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>106.9</td><td rowspan=1 colspan=1>100.6</td></tr><tr><td rowspan=1 colspan=1>Caffeine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>99.8</td><td rowspan=1 colspan=1>99.8</td></tr><tr><td rowspan=1 colspan=1>Carbamazepine</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>99.4</td><td rowspan=1 colspan=1>98.9</td></tr><tr><td rowspan=1 colspan=1>Carbamazepine- 10, 11epoxide</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>98.9</td><td rowspan=1 colspan=1>98.9</td></tr><tr><td rowspan=1 colspan=1>10-Hydroxy carbamazepine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>102.8</td><td rowspan=1 colspan=1>100.4</td></tr><tr><td rowspan=1 colspan=1>Chloramphenicol</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>101.4</td><td rowspan=1 colspan=1>96.7</td></tr><tr><td rowspan=1 colspan=1>Chlorpromazine</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>103.1</td><td rowspan=1 colspan=1>100.8</td></tr><tr><td rowspan=1 colspan=1>Citalopram</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>102.8</td><td rowspan=1 colspan=1>100.8</td></tr><tr><td rowspan=1 colspan=1>Clobazam</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>96.3</td><td rowspan=1 colspan=1>108.0</td></tr><tr><td rowspan=1 colspan=1>Clonazepam</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>101.2</td><td rowspan=1 colspan=1>101.4</td></tr><tr><td rowspan=1 colspan=1>Cyclosporin A</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>95.1</td><td rowspan=1 colspan=1>97.2</td></tr><tr><td rowspan=1 colspan=1>Diazepam</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>102.6</td><td rowspan=1 colspan=1>100.5</td></tr><tr><td rowspan=1 colspan=1>Digoxin</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>103.0</td><td rowspan=1 colspan=1>101.8</td></tr><tr><td rowspan=1 colspan=1>Doxepin</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>103.9</td><td rowspan=1 colspan=1>101.2</td></tr><tr><td rowspan=1 colspan=1>Erythromycin</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>97.9</td><td rowspan=1 colspan=1>98.9</td></tr><tr><td rowspan=1 colspan=1>Ethanol</td><td rowspan=1 colspan=1>4000 (0.4%)</td><td rowspan=1 colspan=1>105.2</td><td rowspan=1 colspan=1>99.3</td></tr><tr><td rowspan=1 colspan=1>Ethotoin</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>97.1</td><td rowspan=1 colspan=1>97.5</td></tr><tr><td rowspan=1 colspan=1>Ethosuximide</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>95.8</td><td rowspan=1 colspan=1>99.6</td></tr><tr><td rowspan=1 colspan=1>Felbamate</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>98.2</td><td rowspan=1 colspan=1>99.1</td></tr><tr><td rowspan=1 colspan=1>Fluoxetine</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>103.8</td><td rowspan=1 colspan=1>101.2</td></tr><tr><td rowspan=1 colspan=1>Furosemide</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95.2</td><td rowspan=1 colspan=1>98.0</td></tr></table>

ARK Diagnostics, Inc. - 510(k) Summary ARK Gabapentin Assay

<table><tr><td rowspan=2 colspan=1>Compound</td><td rowspan=2 colspan=1>Concentration(μg/mL)</td><td rowspan=1 colspan=2>Percentage Recovery</td></tr><tr><td rowspan=1 colspan=1>Gabapentin(2 μg/mL)</td><td rowspan=1 colspan=1>Gabapentin(20 μg/mL)</td></tr><tr><td rowspan=1 colspan=1>Gentamicin</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100.0</td><td rowspan=1 colspan=1>100.4</td></tr><tr><td rowspan=1 colspan=1>Haloperidol</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>102.5</td><td rowspan=1 colspan=1>101.7</td></tr><tr><td rowspan=1 colspan=1>Heparin</td><td rowspan=1 colspan=1>200 U/mL</td><td rowspan=1 colspan=1>94.8</td><td rowspan=1 colspan=1>96.2</td></tr><tr><td rowspan=1 colspan=1>Ibuprofen</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>96.5</td><td rowspan=1 colspan=1>96.9</td></tr><tr><td rowspan=1 colspan=1>Imipramine</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>101.2</td><td rowspan=1 colspan=1>101.1</td></tr><tr><td rowspan=1 colspan=1>Kanamycin B</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>96.7</td><td rowspan=1 colspan=1>101.3</td></tr><tr><td rowspan=1 colspan=1>Lamotrigine</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>102.9</td><td rowspan=1 colspan=1>95.9</td></tr><tr><td rowspan=1 colspan=1>Levetiracetam</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>97.4</td><td rowspan=1 colspan=1>96.0</td></tr><tr><td rowspan=1 colspan=1>Lidocaine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>97.7</td><td rowspan=1 colspan=1>98.7</td></tr><tr><td rowspan=1 colspan=1>Lincomycin</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>102.4</td><td rowspan=1 colspan=1>100.4</td></tr><tr><td rowspan=1 colspan=1>Mephenytoin</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100.6</td><td rowspan=1 colspan=1>99.6</td></tr><tr><td rowspan=1 colspan=1>Mesoridazine</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>106.2</td><td rowspan=1 colspan=1>96.2</td></tr><tr><td rowspan=1 colspan=1>Methicillin</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>101.5</td><td rowspan=1 colspan=1>98.0</td></tr><tr><td rowspan=1 colspan=1>Naproxen</td><td rowspan=1 colspan=1>600</td><td rowspan=1 colspan=1>100.2</td><td rowspan=1 colspan=1>97.3</td></tr><tr><td rowspan=1 colspan=1>Neomycin</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>97.8</td><td rowspan=1 colspan=1>102.1</td></tr><tr><td rowspan=1 colspan=1>Niacin</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>98.9</td><td rowspan=1 colspan=1>100.3</td></tr><tr><td rowspan=1 colspan=1>Nitrazepam</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>96.5</td><td rowspan=1 colspan=1>97.5</td></tr><tr><td rowspan=1 colspan=1>Nortriptyline</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>101.6</td><td rowspan=1 colspan=1>97.1</td></tr><tr><td rowspan=1 colspan=1>Olanzapine</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>99.9</td><td rowspan=1 colspan=1>98.5</td></tr><tr><td rowspan=1 colspan=1>Oxcarbazepine</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>100.9</td><td rowspan=1 colspan=1>100.8</td></tr><tr><td rowspan=1 colspan=1>Paroxetine</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>102.4</td><td rowspan=1 colspan=1>96.0</td></tr><tr><td rowspan=1 colspan=1>2-phenyl-ethyl-malonamide(PEMA)</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>105.8</td><td rowspan=1 colspan=1>98.7</td></tr><tr><td rowspan=1 colspan=1>Penicillin V</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95.8</td><td rowspan=1 colspan=1>99.0</td></tr><tr><td rowspan=1 colspan=1>Perphenazine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>102.4</td><td rowspan=1 colspan=1>99.0</td></tr><tr><td rowspan=1 colspan=1>Phenobarbital</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>100.3</td><td rowspan=1 colspan=1>98.3</td></tr><tr><td rowspan=1 colspan=1>Phenytoin</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>96.9</td><td rowspan=1 colspan=1>93.6</td></tr><tr><td rowspan=1 colspan=1>Primidone</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>93.0</td><td rowspan=1 colspan=1>99.1</td></tr><tr><td rowspan=1 colspan=1>Procainamide</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95.9</td><td rowspan=1 colspan=1>95.9</td></tr><tr><td rowspan=1 colspan=1>Prochlorperazine</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>97.8</td><td rowspan=1 colspan=1>98.7</td></tr><tr><td rowspan=1 colspan=1>Ranitidine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>97.2</td><td rowspan=1 colspan=1>98.3</td></tr><tr><td rowspan=1 colspan=1>Rifampin</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95.3</td><td rowspan=1 colspan=1>102.4</td></tr><tr><td rowspan=1 colspan=1>Risperidone</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>101.8</td><td rowspan=1 colspan=1>103.2</td></tr><tr><td rowspan=1 colspan=1>Sertraline</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>98.5</td><td rowspan=1 colspan=1>97.5</td></tr><tr><td rowspan=1 colspan=1>Spectinomycin</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>98.3</td><td rowspan=1 colspan=1>102.1</td></tr><tr><td rowspan=1 colspan=1>Stiripentol</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95.9</td><td rowspan=1 colspan=1>96.7</td></tr><tr><td rowspan=1 colspan=1>Sulfamethoxazole</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>97.5</td><td rowspan=1 colspan=1>98.0</td></tr><tr><td rowspan=1 colspan=1>Theophylline</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>103.0</td><td rowspan=1 colspan=1>100.5</td></tr><tr><td rowspan=1 colspan=1>Thioridazine</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>102.6</td><td rowspan=1 colspan=1>102.5</td></tr><tr><td rowspan=1 colspan=1>Tobramycin</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>94.6</td><td rowspan=1 colspan=1>100.3</td></tr><tr><td rowspan=1 colspan=1>Tiagabine</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>91.6</td><td rowspan=1 colspan=1>97.9</td></tr><tr><td rowspan=1 colspan=1>Topiramate</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>96.9</td><td rowspan=1 colspan=1>96.9</td></tr></table>

ARK Diagnostics, Inc. - 510(k) Summary ARK Gabapentin Assay

<table><tr><td rowspan=2 colspan=1>Compound</td><td rowspan=2 colspan=1>Concentration(μg/mL)</td><td rowspan=1 colspan=2>Percentage Recovery</td></tr><tr><td rowspan=1 colspan=1>Gabapentin(2 μg/mL)</td><td rowspan=1 colspan=1>Gabapentin(20 μg/mL)</td></tr><tr><td rowspan=1 colspan=1>Trimethoprim</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>96.7</td><td rowspan=1 colspan=1>99.0</td></tr><tr><td rowspan=1 colspan=1>Valproic Acid</td><td rowspan=1 colspan=1>600</td><td rowspan=1 colspan=1>96.7</td><td rowspan=1 colspan=1>96.9</td></tr><tr><td rowspan=1 colspan=1>Vancomycin</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>100.3</td><td rowspan=1 colspan=1>99.8</td></tr><tr><td rowspan=1 colspan=1>Vigabatrin</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>101.3</td><td rowspan=1 colspan=1>99.9</td></tr><tr><td rowspan=1 colspan=1>Zonisamide</td><td rowspan=1 colspan=1>400</td><td rowspan=1 colspan=1>98.6</td><td rowspan=1 colspan=1>104.1</td></tr></table>

# L-Amino Acid Interference

The L-amino acids listed below resulted in ${ < } 1 0 \%$ error in detecting gabapentin at the concentrations tested.

<table><tr><td rowspan=2 colspan=1>Compound</td><td rowspan=2 colspan=1>Concentration(μg/mL)</td><td rowspan=1 colspan=2>Percentage Recovery</td></tr><tr><td rowspan=1 colspan=1>Gabapentin(2 μg/mL)</td><td rowspan=1 colspan=1>Gabapentin(20 μg/mL)</td></tr><tr><td rowspan=1 colspan=1>L-Arginine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>96.9</td><td rowspan=1 colspan=1>104.4</td></tr><tr><td rowspan=1 colspan=1>L-Asparagine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95.1</td><td rowspan=1 colspan=1>101.8</td></tr><tr><td rowspan=1 colspan=1>L-Aspartic Acid</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>93.9</td><td rowspan=1 colspan=1>102.0</td></tr><tr><td rowspan=1 colspan=1>L-Cysteine</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>92.6</td><td rowspan=1 colspan=1>101.9</td></tr><tr><td rowspan=1 colspan=1>L-Glutamic Acid</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95.7</td><td rowspan=1 colspan=1>101.4</td></tr><tr><td rowspan=1 colspan=1>L-Glycine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>98.0</td><td rowspan=1 colspan=1>100.8</td></tr><tr><td rowspan=1 colspan=1>L-Histidine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>92.2</td><td rowspan=1 colspan=1>102.5</td></tr><tr><td rowspan=1 colspan=1>L-Isoleucine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>92.2</td><td rowspan=1 colspan=1>101.9</td></tr><tr><td rowspan=1 colspan=1>L-Leucine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>96.3</td><td rowspan=1 colspan=1>101.5</td></tr><tr><td rowspan=1 colspan=1>L-Methionine</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>93.3</td><td rowspan=1 colspan=1>100.9</td></tr><tr><td rowspan=1 colspan=1>L-Phenylalanine</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>94.4</td><td rowspan=1 colspan=1>99.6</td></tr><tr><td rowspan=1 colspan=1>L-Serine</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>95.1</td><td rowspan=1 colspan=1>99.3</td></tr><tr><td rowspan=1 colspan=1>L-Threonine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>95.6</td><td rowspan=1 colspan=1>100.7</td></tr><tr><td rowspan=1 colspan=1>L-Tyrosine</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>93.9</td><td rowspan=1 colspan=1>99.0</td></tr><tr><td rowspan=1 colspan=1>L-Alanine</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>98.9</td><td rowspan=1 colspan=1>97.0</td></tr><tr><td rowspan=1 colspan=1>L-Lysine</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>97.8</td><td rowspan=1 colspan=1>98.2</td></tr><tr><td rowspan=1 colspan=1>L-Proline</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>96.0</td><td rowspan=1 colspan=1>98.3</td></tr><tr><td rowspan=1 colspan=1>L-Valine</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>97.5</td><td rowspan=1 colspan=1>97.7</td></tr><tr><td rowspan=1 colspan=1>L-Tryptophan</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>98.0</td><td rowspan=1 colspan=1>99.1</td></tr><tr><td rowspan=1 colspan=1>L-Glutamine</td><td rowspan=1 colspan=1>350</td><td rowspan=1 colspan=1>97.3</td><td rowspan=1 colspan=1>96.9</td></tr></table>

# Drug that Interferes - Pregabalin

Pregabalin was analyzed from 15 to 100 µg/mL in the presence of either Low (2 µg/mL) or High (20 µg/mL) gabapentin. High concentrations of pregabalin may interfere by elevating the measurement of gabapentin. Pregabalin plasma levels in patients under therapy have been reported to range from approximately 0.2 to $1 4 . 2 ~ \mu \mathrm { g / m L }$ . Excessive pregabalin levels up to 60 $\mu \mathrm { g } / \mathrm { m L }$ in combination with lamotrigine in a self poisoning incident have been reported. The results of interference testing are shown below.

<table><tr><td rowspan=2 colspan=1>Pregabalin(μg/mL)</td><td rowspan=1 colspan=2>Percent Cross-Reactivity</td><td rowspan=1 colspan=2>Percent Recovery</td></tr><tr><td rowspan=1 colspan=1>Gabapentin(2 μg/mL)</td><td rowspan=1 colspan=1>Gabapentin(20 μg/mL)</td><td rowspan=1 colspan=1>Gabapentin(2 μg/mL)</td><td rowspan=1 colspan=1>Gabapentin(20 μg/mL)</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>1.10</td><td rowspan=1 colspan=1>1.95</td><td rowspan=1 colspan=1>156.9</td><td rowspan=1 colspan=1>109.7</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>1.18</td><td rowspan=1 colspan=1>2.06</td><td rowspan=1 colspan=1>130.6</td><td rowspan=1 colspan=1>105.1</td></tr><tr><td rowspan=1 colspan=1>15.</td><td rowspan=1 colspan=1>1.13</td><td rowspan=1 colspan=1>-1.47</td><td rowspan=1 colspan=1>108.9</td><td rowspan=1 colspan=1>98.9</td></tr></table>

Car should be taken when interpretng AR Gabapentn results f pregabalin s aso b administered to the patient.

# Anticoagulants

Studies were conducted to determine the performance characteristics of the assay for both serum and plasma samples containing gabapentin. The results indicate that there is no significant difference between the recovery of gabapentin in serum or plasma.

# Sample Stability

Testing of fresh specimens is preferred. Clarified specimens may be stored up to one week at 2 to 8°C. If testing will be delayed more than one week, specimens may be stored frozen (≤ -10°C) up to four weeks prior to being tested (acceptance criterion $\pm \ : 1 0 \%$ .Care should be taken to limit the number of freeze-thaw cycles. Specimens were shown to withstand 3 freeze-thaw cycles when stored at ${ \bf - 2 0 ^ { \circ } C }$ .

# On-Board Stability

Calibration Curve Stability: A stored calibration was effective up to 84 days based on supporting data. Curve stability may depend on individual laboratory performance.

Reagent on-board stability: Reagents were effective when stored after transfer to analyzer sp reaget containers for up to at least 4 days basedon supporting data. In-use stabilty calibrator and controls was also demonstrated.

Accelerated OPEN stability of calibrators and controls:

Calibrators and controls were shown to be stable OPEN in accelerated stability at 37°C for seven (7) days. Once opened vials may be stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ for 12 months.

# 807.92 (b)(3): Conclusions from Nonclinical Testing

As summarized above, the ARK Gabapentin Assay, the ARK Gabapentin Calibrator and the ARK Gabapentin Control are substantially equivalent to the ARK™ Topiramate Assay system. The ARK Gabapentin Assay system was shown to be safe and effective for its intended use based on performance studies.

ARK Diagnostics, Inc. c/o Johnny Valdez President 1190 Bordeaux Drive Sunnyvale, CA 94089

# NOV 2 3 2010

Re: k101574   
Trade/Device Name: ARKTM Gabapentin Assay, ARKTM Gabapentin Calibrator, and ARKTM Gabapentin Control   
Regulation Number: 21 CFR 862.3350   
Regulation Name: Diphenylhydantoin Test System.   
Regulatory Class: Class II   
Product Codes: OTF, DLJ, LAS   
Dated: November 15, 2010   
Received: November 16, 2010

Dear Mr. Valdez,

We have reviewed your Section 5 10(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

This letter will allow you to begin marketing your device as described in your Section 510(k) a marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

Page 2 -

If you desire specific advice for your device on our labeling regulation (21 CFR Parts 801 and 809), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796- 5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notfication" (1 CFR Part 807.97.For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Gc.

Coulrthey Harper, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device   
Evaluation and Safety   
Center for Devices and Radiological Health

# Indication for Use

# 510(K) Number (if known):

# Device Name:

ARKTM Gabapentin Assay ARKTM Gabapentin Calibrator ARK TM Gabapentin Control

# Indications for Use:

The ARK™M Gabapentin Assay is a homogeneous enzyme immunoassay intended for the quantitative determination of gabapentin in human serum or plasma on automated clinical chemistry analyzers.

Gabapentin concentrations can be used as an aid in management of patients treate with gabapentin.

The ARKTM Gabapentin Calibrator is intended for use in calibration of the ARK Gabapentin Assay.

The ARKTM Gabapentin Control is intended for use in quality control of the ARK Gabapentin Assay.

Prescription Use X (21 CFR Part 801 Subpart D)

Over the Counter Use (21 CFR Part 801 Subpart C)

Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

![](images/d417c7ad357323dfb2adb0ae3510045bd70846215b53237d7cbaa7711912df16.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

# 510(k) K101574

ARK Gabapentin Assay - Indications/Intended Use ARK Diagnostics, Inc.